ChemoCentryx Completes Enrollment for Phase II/III Crohn's Disease Trial
Posted on: Friday, 13 June 2008, 09:00 CDT
ChemoCentryx has completed enrollment of 436 patients in the company's Protect-1, a Phase II/III clinical trial of Traficet-EN in patients with moderate-to-severe Crohn's disease.
This clinical trial comprises three discrete phases which allows for evaluation of efficacy and safety of Traficet-EN in inducing a clinical response or remission, as well as maintaining response/remission in Crohn's disease over a combined total of 12 months. The company is on track to report data from the induction phase of this trial in the fourth quarter of 2008.
Protect-1 is a randomized, placebo-controlled, double-blind study that includes a 12-week 'induction period', during which patients with moderate-to-severe Crohn's disease will receive either Traficet-EN or a placebo in order to evaluate the drug's ability to induce a clinical response or remission.
The induction phase of the study is followed by a four-week, open label 'active period', during which all subjects receive Traficet-EN. Patients who achieve a pre-specified reduction in disease severity are re-randomized to active drug or placebo for an additional 36-week 'maintenance period', thereby permitting an evaluation of the drug's ability to maintain a treatment response.
The primary efficacy endpoint in the induction Phase of the study is the attainment of a clinical response defined as a decrease from baseline in the Crohn's disease activity index score of at least 70 points.
In a separate clinical trial, Traficet-EN is also being evaluated for patients with celiac disease, a sensitivity to gluten and gluten derivatives in which digestive tract T cells are thought to play an important role.
Source: Datamonitor
Related Articles
- Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
- 21 Hospitals in Louisiana, Mississippi and Tennessee Come Together to Focus on Improving Clinical Quality and Patient Safety
- Altus Pharmaceuticals Reports Last Patient Visit Of Trizytek(TM) Phase 3 Efficacy Trial
- ACTOS(R) (Pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients With Type 2 Diabetes
- B.C. Wins Showdown With Private Clinic; Clinic Won't Bill Patients
- Nuvelo Announces Completion of Patient Enrollment in SONOMA-2, First Phase 3 Trial of Alfimeprase in Central Venous Catheter Occlusion
- Incidence of End-Stage Renal Disease in Patients With Type 1 Diabetes Was 7.8% at 30 Years After Diagnosis/COMMENTARY
- Clinical Characteristics and Treatment Responses of Tuberculosis in Patients With Malignancy Receiving Anticancer Chemotherapy*
- Effects of Lipo-Prostaglandin E^Sub 1^ on Pulmonary Hemodynamics and Clinical Outcomes in Patients With Pulmonary Arterial Hypertension*
- Orlistat Augments Postprandial Increases in Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients: Response to Damci Et Al./ Orlistat Augments Postprandial Increases In Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients: Response to Horowitz Et
 |
 |
User Comments (0)
RSS Feeds